177 related articles for article (PubMed ID: 21156931)
1. Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES).
Niu Y; Gong Y; Langaee TY; Davis HM; Elewa H; Beitelshees AL; Moss JI; Cooper-Dehoff RM; Pepine CJ; Johnson JA
Circ Cardiovasc Genet; 2010 Dec; 3(6):548-55. PubMed ID: 21156931
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomic association of nonsynonymous SNPs in SIGLEC12, A1BG, and the selectin region and cardiovascular outcomes.
McDonough CW; Gong Y; Padmanabhan S; Burkley B; Langaee TY; Melander O; Pepine CJ; Dominiczak AF; Cooper-Dehoff RM; Johnson JA
Hypertension; 2013 Jul; 62(1):48-54. PubMed ID: 23690342
[TBL] [Abstract][Full Text] [Related]
3. KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST).
Beitelshees AL; Gong Y; Wang D; Schork NJ; Cooper-Dehoff RM; Langaee TY; Shriver MD; Sadee W; Knot HJ; Pepine CJ; Johnson JA;
Pharmacogenet Genomics; 2007 Sep; 17(9):719-29. PubMed ID: 17700361
[TBL] [Abstract][Full Text] [Related]
4. Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/β-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) Trials.
Magvanjav O; Gong Y; McDonough CW; Chapman AB; Turner ST; Gums JG; Bailey KR; Boerwinkle E; Beitelshees AL; Tanaka T; Kubo M; Pepine CJ; Cooper-DeHoff RM; Johnson JA
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29097388
[TBL] [Abstract][Full Text] [Related]
5. G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension.
Vandell AG; Lobmeyer MT; Gawronski BE; Langaee TY; Gong Y; Gums JG; Beitelshees AL; Turner ST; Chapman AB; Cooper-DeHoff RM; Bailey KR; Boerwinkle E; Pepine CJ; Liggett SB; Johnson JA
Hypertension; 2012 Oct; 60(4):957-64. PubMed ID: 22949529
[TBL] [Abstract][Full Text] [Related]
6. CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response.
Beitelshees AL; Navare H; Wang D; Gong Y; Wessel J; Moss JI; Langaee TY; Cooper-DeHoff RM; Sadee W; Pepine CJ; Schork NJ; Johnson JA
Circ Cardiovasc Genet; 2009 Aug; 2(4):362-70. PubMed ID: 20031608
[TBL] [Abstract][Full Text] [Related]
7. Liver X receptor α gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study.
Price ET; Pacanowski MA; Martin MA; Cooper-DeHoff RM; Pepine CJ; Zineh I; Johnson JA
Pharmacogenet Genomics; 2011 Jun; 21(6):333-40. PubMed ID: 21562465
[TBL] [Abstract][Full Text] [Related]
8. Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers.
Bakris GL; Cooper-Dehoff RM; Zhou Q; Kupfer S; Champion A; Pepine CJ;
Am J Cardiovasc Drugs; 2007; 7 Suppl 1():25-9. PubMed ID: 19845074
[TBL] [Abstract][Full Text] [Related]
9. [Association between CACNB2 gene polymorphisms and essential hypertension].
Sun Q; Wang X; Huang Y; Hu Y; Tang J; Lin Y; Niu Y; Wang X; Du B
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Jun; 30(3):340-4. PubMed ID: 23744328
[TBL] [Abstract][Full Text] [Related]
10. Safety of beta-blocker and calcium channel blocker antihypertensive drugs in pregnancy: a Mendelian randomization study.
Ardissino M; Slob EAW; Rajasundaram S; Reddy RK; Woolf B; Girling J; Johnson MR; Ng FS; Gill D
BMC Med; 2022 Sep; 20(1):288. PubMed ID: 36064525
[TBL] [Abstract][Full Text] [Related]
11. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
Pepine CJ; Handberg EM; Cooper-DeHoff RM; Marks RG; Kowey P; Messerli FH; Mancia G; Cangiano JL; Garcia-Barreto D; Keltai M; Erdine S; Bristol HA; Kolb HR; Bakris GL; Cohen JD; Parmley WW;
JAMA; 2003 Dec; 290(21):2805-16. PubMed ID: 14657064
[TBL] [Abstract][Full Text] [Related]
12. A Study of Antihypertensive Drugs and Depressive Symptoms (SADD-Sx) in patients treated with a calcium antagonist versus an atenolol hypertension Treatment Strategy in the International Verapamil SR-Trandolapril Study (INVEST).
Ried LD; Tueth MJ; Handberg E; Kupfer S; Pepine CJ;
Psychosom Med; 2005; 67(3):398-406. PubMed ID: 15911902
[TBL] [Abstract][Full Text] [Related]
13. Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study).
Brunner M; Cooper-DeHoff RM; Gong Y; Karnes JH; Langaee TY; Pepine CJ; Johnson JA;
Am J Cardiol; 2007 Jun; 99(11):1549-54. PubMed ID: 17531579
[TBL] [Abstract][Full Text] [Related]
14. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy.
Bangalore S; Messerli FH; Cohen JD; Bacher PH; Sleight P; Mancia G; Kowey P; Zhou Q; Champion A; Pepine CJ;
Am Heart J; 2008 Aug; 156(2):241-7. PubMed ID: 18657652
[TBL] [Abstract][Full Text] [Related]
15. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension.
Pepine CJ; Handberg-Thurmond E; Marks RG; Conlon M; Cooper-DeHoff R; Volkers P; Zellig P
J Am Coll Cardiol; 1998 Nov; 32(5):1228-37. PubMed ID: 9809930
[TBL] [Abstract][Full Text] [Related]
16. Adverse Cardiovascular Outcomes and Antihypertensive Treatment: A Genome-Wide Interaction Meta-Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies.
McDonough CW; Warren HR; Jack JR; Motsinger-Reif AA; Armstrong ND; Bis JC; House JS; Singh S; El Rouby NM; Gong Y; Mychaleckyj JC; Rotroff DM; Benavente OR; Caulfield MJ; Doria A; Pepine CJ; Psaty BM; Glorioso V; Glorioso N; Hiltunen TP; Kontula KK; Arnett DK; Buse JB; Irvin MR; Johnson JA; Munroe PB; Wagner MJ; Cooper-DeHoff RM
Clin Pharmacol Ther; 2021 Sep; 110(3):723-732. PubMed ID: 34231218
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide association study identifies pharmacogenomic loci linked with specific antihypertensive drug treatment and new-onset diabetes.
Chang SW; McDonough CW; Gong Y; Johnson TA; Tsunoda T; Gamazon ER; Perera MA; Takahashi A; Tanaka T; Kubo M; Pepine CJ; Johnson JA; Cooper-DeHoff RM
Pharmacogenomics J; 2018 Jan; 18(1):106-112. PubMed ID: 27670767
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients.
Lobmeyer MT; Wang L; Zineh I; Turner ST; Gums JG; Chapman AB; Cooper-DeHoff RM; Beitelshees AL; Bailey KR; Boerwinkle E; Pepine CJ; Johnson JA
Pharmacogenet Genomics; 2011 Jan; 21(1):42-9. PubMed ID: 21127457
[TBL] [Abstract][Full Text] [Related]
19. INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study.
Cooper-DeHoff RM; Handberg EM; Mancia G; Zhou Q; Champion A; Legler UF; Pepine CJ
Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1329-40. PubMed ID: 19900016
[TBL] [Abstract][Full Text] [Related]
20. Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes.
Karnes JH; Gong Y; Pacanowski MA; McDonough CW; Arwood MJ; Langaee TY; Pepine CJ; Johnson JA; Cooper-Dehoff RM
Pharmacogenet Genomics; 2013 Dec; 23(12):697-705. PubMed ID: 24128935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
